» Articles » PMID: 18232012

Homogeneity of Active Demyelinating Lesions in Established Multiple Sclerosis

Overview
Journal Ann Neurol
Specialty Neurology
Date 2008 Jan 31
PMID 18232012
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Four different patterns of demyelination have been described in active demyelinating lesions of multiple sclerosis (MS) patients that were biopsied shortly after disease onset. These patterns were suggested to represent heterogeneity of the underlying pathogenesis. The aim of this study was to determine whether lesion heterogeneity also exists in an unselected collection of autopsy material from patients with established MS.

Methods: All MS brain tissue available in the VU Medical Center was assessed for the presence of active demyelinating lesions using magnetic resonance imaging-guided sampling and immunohistochemistry. Tissue blocks containing active demyelinating lesions were evaluated for the presence of complement and antibody deposition, oligodendrocyte apoptosis, differential loss of myelin proteins, and hypoxia-like damage using histology, immunohistochemistry, and confocal microscopy. Blocks with active demyelinating lesions were compared with blocks with active (nondemyelinating) and inactive lesions.

Results: Complement and antibodies were consistently associated with macrophages in areas of active demyelination. Preferential loss of myelin proteins, extensive hypoxia-like damage, and oligodendrocyte apoptosis were absent or rare. This pattern was observed in all tissue blocks containing active demyelinating lesions; lesion heterogeneity between patients was not found.

Interpretation: The immunopathological appearance of active demyelinating lesions in established MS is uniform. Initial heterogeneity of demyelinating lesions in the earliest phase of MS lesion formation may disappear over time as different pathways converge in one general mechanism of demyelination. Consistent presence of complement, antibodies, and Fcgamma receptors in phagocytic macrophages suggests that antibody- and complement-mediated myelin phagocytosis is the dominant mechanism of demyelination in established MS.

Citing Articles

Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology.

DiCillo E, Kountikov E, Zhu M, Lanker S, Harlow D, Piette E J Clin Invest. 2025; 135(5).

PMID: 40026247 PMC: 11870742. DOI: 10.1172/JCI171948.


Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis.

Oechtering J, Schaedelin S, Stein K, Maceski A, Melie-Garcia L, Benkert P Neurol Neuroimmunol Neuroinflamm. 2025; 12(2):e200361.

PMID: 39752618 PMC: 11702906. DOI: 10.1212/NXI.0000000000200361.


Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.


Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions.

Lerma-Martin C, Badia-I-Mompel P, Ramirez Flores R, Sekol P, Schafer P, Riedl C Nat Neurosci. 2024; 27(12):2354-2365.

PMID: 39501036 PMC: 11614744. DOI: 10.1038/s41593-024-01796-z.


Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways.

Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C J Neuroinflammation. 2024; 21(1):276.

PMID: 39465429 PMC: 11514909. DOI: 10.1186/s12974-024-03267-5.